BioLargo, Inc. BLGO

Company Overview

BioLargo, Inc. is a U.S.-based environmental engineering and specialty technology company focused on water treatment, air quality control, environmental remediation, and health and wellness technologies. The company operates primarily in the environmental services and cleantech industries, developing proprietary technologies intended to address contamination, waste management, industrial emissions, and resource recovery challenges. BioLargo generates revenue through engineering services, equipment sales, licensing agreements, product commercialization, and environmental treatment solutions. Its primary customer base includes municipal water utilities, industrial operators, commercial facilities, government-related entities, and specialized environmental service providers.

The company’s principal business lines include advanced oxidation water treatment systems, PFAS contamination mitigation technologies, odor and volatile organic compound control systems, and engineering consulting services. BioLargo has positioned itself around proprietary environmental technologies designed to improve treatment efficiency while reducing operational costs and environmental impact. Founded in the early 2000s, the company evolved from a specialty product and consumer-focused business into an environmental technology platform through internal research, acquisitions, and strategic commercialization initiatives centered on water and air treatment innovation.

Business Operations

BioLargo conducts operations through several business units and subsidiaries, including BioLargo Water, BioLargo Engineering, Science & Technologies (BLEST), ONM Environmental, and Clyra Medical Technologies. The company’s operations are centered on developing and commercializing technologies such as the Advanced Oxidation System (AOS) for water purification, PFAS treatment solutions, odor and emissions control systems, and engineering consulting services for environmental infrastructure projects. Revenue is generated through equipment deployment, engineering contracts, technology licensing, product sales, and recurring environmental service arrangements.

The company operates primarily in the United States but also pursues international licensing, distribution, and commercialization opportunities. BioLargo controls a portfolio of patents and intellectual property related to oxidation chemistry, filtration systems, and industrial environmental treatment applications. Strategic relationships with municipal agencies, industrial operators, and commercialization partners support market adoption of its technologies. The company has also pursued joint development arrangements and commercialization partnerships tied to environmental remediation and medical technology applications.

Strategic Position & Investments

BioLargo’s strategic direction has focused on expanding commercialization of its PFAS remediation technologies, scaling water treatment deployments, and growing its environmental engineering capabilities. The company has invested significantly in research and development tied to contamination treatment, particularly for per- and polyfluoroalkyl substances (PFAS), which have become a major regulatory and environmental concern in the United States and internationally. BioLargo has emphasized a strategy of combining proprietary technology development with engineering services to create integrated environmental solutions for industrial and municipal customers.

Key investments have included continued development of the AOS water treatment platform and expansion of environmental engineering operations through BLEST. The company has also maintained involvement in medical technology through Clyra Medical Technologies, which develops antimicrobial and wound-care related products. BioLargo’s positioning in emerging environmental sectors is closely tied to tightening environmental regulations, water infrastructure modernization, and demand for sustainable treatment technologies. Public filings and company disclosures consistently identify PFAS treatment, advanced oxidation chemistry, and environmental infrastructure support as core long-term growth areas.

Geographic Footprint

BioLargo is headquartered in Westminster, California, and its primary operational footprint is concentrated in the United States. The company’s technologies and engineering services have targeted customers across municipal, industrial, and commercial markets in multiple U.S. regions, particularly in sectors affected by water contamination, air emissions management, and environmental compliance requirements.

Although BioLargo’s direct operational scale outside the U.S. remains comparatively limited relative to larger multinational environmental firms, the company has pursued international commercialization opportunities through licensing arrangements, distribution relationships, and technology demonstrations. Its environmental technologies have relevance in global markets addressing water scarcity, industrial pollution, and regulatory-driven remediation initiatives, including opportunities in North America, parts of Europe, and select international industrial markets.

Leadership & Governance

BioLargo’s leadership team has emphasized technology commercialization, environmental sustainability, and intellectual property development as central elements of the company’s strategy. The company was co-founded by Dennis P. Calvert, who has remained a central executive figure during BioLargo’s transition toward environmental engineering and cleantech operations. Public communications and regulatory filings describe a leadership philosophy centered on scalable environmental innovation, regulatory alignment, and long-term technology adoption in water and air treatment markets.

Key executives include:

• Dennis P. Calvert – President and Chief Executive Officer
• Kenneth R. Code – Chief Financial Officer
• Randall Moore – President of BioLargo Engineering, Science & Technologies (BLEST)
• Tonya Chandler – Chief Operating Officer
• Joe Provenzano – President of BioLargo Water

The company operates under a public-company governance structure consistent with U.S. reporting requirements and files regular disclosures through the SEC, including annual reports on Form 10-K and quarterly reports on Form 10-Q. Publicly available filings, investor materials, and independent financial reporting sources generally align regarding BioLargo’s business structure and strategic focus areas.